CardioSignal appoints Tero-Pekka Alastalo to boost market entry in United States
As the Chief Medical Officer and General Manager of US operations, Dr. Alastalo brings CardioSignal expertise, access and a strong track record to establishing operations in the United States. Dr. Alastalo is a co-founder of the clinical genetic testing company Blueprint Genetics, which was acquired by Quest Diagnostics in 2020.
CardioSignal is a brand and a product by Precordior, a Finnish health technology company that is preparing for US market entry to introduce a disruptive smartphone application for the detection of heart diseases. Based on a decade of research and algorithm development, CardioSignal’s patented motion sensor technology enables the accurate evaluation of cardiac motion, and with it, accurate assessment of heart conditions.
“I am very excited for this opportunity to join the CardioSignal team and help them drive the development and commercialization of this amazing technology. CardioSignal has the potential to revolutionize the detection of heart diseases and improve access to early management and improved outcomes. Heart diseases are a major economic burden on our healthcare system and a major contributor to decreased quality of life. We need new technologies and approaches to bring relief to this burden, as current healthcare systems have not been successful in this,” says Tero-Pekka Alastalo, General Manager, US operations.
Cardiovascular diseases are the leading cause of death globally. Of all deaths, 32% are estimated to be caused by a cardiovascular disease, and this number is even higher in developing countries. Of these deaths, 85% are caused by heart attack and stroke. Early detection of cardiovascular diseases has been considered essential when aiming for early management and improved outcome(1).
“Having Tero-Pekka Alastalo on board is a major step in our efforts to build US operations and fuel our global growth. His strategic, operational and medical expertise are an integral part of bringing this unique mobile-app technology to the hands of consumers globally. In the coming year, we will be significantly focusing on product development, customer experience and continued scientific efforts in the United States,” says CEO Juuso Blomster.
In brief:
CardioSignal is a mobile application that uses the built-in sensors of a smartphone to detect heart motion.
CardioSignal is approved as a medical device in Europe to detect atrial fibrillation, with plans to expand to other types of heart disease.
Results of clinical trials in heart failure and coronary disease are expected to be completed in early 2022.
The app works by placing the phone on the chest for one minute. The first-line application analyzes whether there are signs of atrial fibrillation and provides the results immediately.
Atrial fibrillation can be dangerously asymptomatic in at least one third of all patients. For this reason, regular monitoring, especially in the at-risk population, has been suggested as an effective path to early diagnosis and minimizing the risk of costly and often detrimental complications.
More information: www.cardiosignal.com.
Tero-Pekka Alastalo (MD, PhD)
Tero-Pekka Alastalo is the Chief Medical Officer and General Manager of CardioSignal’s operations in the United States. He is based in San Francisco, CA. He has an MD-PhD degree and is specialized in pediatric cardiology. He did his postdoctoral training at Stanford University School of Medicine on the molecular genetic mechanisms of cardiovascular diseases. Tero-Pekka Alastalo is a co-founder of the clinical genetic testing company Blueprint Genetics.
Further information
Juuso Blomster, CEO, juuso.blomster@cardiosignal.com
Tero-Pekka Alastalo, GM, US Operations, tero-pekka.alastalo@cardiosignal.com
Juulia Simonen (Communications) juulia.simonen@cardiosignal.com, tel. +358503059018
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases. CardioSignal is a mobile application and a certified medical device for the detection of atrial fibrillation. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior. www.cardiosignal.com.
1. World Health Organization: Cardiovascular diseases. Updated: 11 June 2021.
